Vertex Pharmaceuticals Inc / Ma SEC filings VRTX
Vertex Pharmaceuticals Inc / Ma has 1,002 filings in SEC EDGAR's recent list, going back to Jun 3, 2020. Its latest annual report, Form ARS, was filed on Apr 2, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 29, 2026 | — |
| DEFA14A | Additional proxy material | Apr 2, 2026 | — |
| DEF 14A | Proxy statement | Apr 2, 2026 | May 13, 2026 |
| DEFA14A | Additional proxy material | Apr 3, 2025 | — |
| DEF 14A | Proxy statement | Apr 3, 2025 | May 14, 2025 |
| DEFA14A | Additional proxy material | Apr 4, 2024 | — |
| DEF 14A | Proxy statement | Apr 4, 2024 | May 15, 2023 |
| DEFA14A | Additional proxy material | Apr 6, 2023 | — |
| DEF 14A | Proxy statement | Apr 6, 2023 | — |
| DEFA14A | Additional proxy material | Apr 7, 2022 | — |
| DEF 14A | Proxy statement | Apr 7, 2022 | May 18, 2022 |
| DEFA14A | Additional proxy material | Apr 8, 2021 | — |
| DEF 14A | Proxy statement | Apr 8, 2021 | May 19, 2021 |
Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Boston, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 875320
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.